Auferstehung?
Seite 1 von 3 Neuester Beitrag: 10.09.22 10:47 | ||||
| Eröffnet am: | 17.11.17 13:24 | von: Heron | Anzahl Beiträge: | 55 |
| Neuester Beitrag: | 10.09.22 10:47 | von: RichyBerlin | Leser gesamt: | 23.868 |
| Forum: | Hot-Stocks | Leser heute: | 13 | |
| Bewertet mit: |  | |||
| Seite: < 1 | 2 | 3 > | ||||
ZIOPHARM Oncology to Host Conference Call on November 20, 2017 at 10:15 a.m. ET to Discuss Updated Clinical Data Presented at the 2017 Annual Meeting of the Society for Neuro-Oncology
By GlobeNewswire, November 17, 2017, 07:00:00 AM EDT
Optionen
--
https://seekingalpha.com/news/...y-after-naming-activist-to-the-board
Optionen
Zahlen für Q2/21
- Cash 77 Mio. $
- MK 494 Mio. $
Closed venture debt financing with Silicon Valley Bank, strengthening balance sheet and extending cash runway into the fourth quarter of 2022
https://ir.ziopharm.com/news-releases/...arter-2021-corporate-updates
Optionen
Belegschaft wird um 50% reduziert
- ungefähr 60 Stellen sollen abgebaut werden
- die Cashreichweite soll dadurch bis H1/23 ausgedehnt werden
- MK 410 Mio. $
https://ir.ziopharm.com/news-releases/...egic-reduction-workforce-and
Optionen
The first patient in its TCR-T Library Phase I/II clinical trial is expected to be dosed in 1H2022
verschoben um mindestens ein halbes Jahr aufgrund von Problemen bei dem geplanten Lieferanten. Nun will man (trotz Stellenabbau ?) eine stabile Entwicklungsmannschaft UND eine eigene Fertigung aufbauen. Kein Wunder wenn man da sparen muss ( und damit allein wird es wohl kaum gehen).
"Alaunos Therapeutics, Inc.
Mon, May 2, 2022, 2:30 PM·4 min read
TCRT
-7.28%
Alaunos Therapeutics, Inc.
First-in-human non-viral TCR-T cell therapy targeting shared hotspot mutations in solid cancers
First clinical product manufactured and administered to a patient using the Company’s in house cGMP manufacturing facility
Expect to report initial data in 2H22
HOUSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced that the first patient has been dosed in its TCR-T Library Phase 1/2 trial targeting KRAS, TP53, and EGFR mutations across six solid tumor indications using the Company’s Sleeping Beauty transposon/transposase technology.
“Dosing the first patient in our TCR-T Library Phase 1/2 trial represents a significant accomplishment for Alaunos. Our team has worked diligently to achieve this milestone and bring our TCR-T cell therapy to cancer patients,” commented Kevin S. Boyle, Sr., Chief Executive Officer of Alaunos. “We believe that our adaptive trial design has the potential to allow us to rapidly and cost effectively identify the recommended phase 2 dose and quickly advance studies in the most promising indications. We look forward to an initial data readout in the second half of this year.”
The Phase 1/2 study is being conducted at The University of Texas MD Anderson Cancer Center and is an open label, dose escalation study, with patients being treated in one of three dose cohorts: 5x109, 4x1010, 1x1011 TCR-T cells. The trial is enrolling patients with non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers that have a matching human leukocyte antigen (HLA) and hotspot mutation pairing in Alaunos’ TCR-T library. The main study objectives are to define the maximum tolerated dose, recommended phase 2 dose and safety profile.
Carl June, M.D., Chairman of the Alaunos Scientific Advisory Board added, “This is a significant accomplishment as the first-in-human dosing of a patient with Sleeping Beauty TCR-T cells...."
Optionen
May 09, 2022 08:30 ET | Source: Alaunos Therapeutics, Inc.
...
HOUSTON, May 09, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced that it will report financial results for the first quarter ended March 31, 2022 on Monday, May 16, 2022, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:30 a.m. ET to provide a corporate update and review the financial results.
The conference call can be accessed by dialing 844-309-0618 (United States) or 661-378-9465 (International) with the conference code 2495623. A live webcast may be accessed using the link here, or by visiting the “Investors” section of the Alaunos website at www.alaunos.com. After the live webcast, the event will be archived on the Company’s website for approximately 30 days after the call.
About Alaunos Therapeutics
Alaunos is a clinical-stage oncology-focused cell therapy company, focused on developing T-cell receptor (TCR) therapies based on its proprietary, non-viral Sleeping Beauty gene transfer technology and its TCR library targeting shared tumor-specific hotspot mutations in key oncogenic genes including KRAS, TP53 and EGFR. The Company has clinical and strategic collaborations with The University of Texas MD Anderson Cancer Center and the National Cancer Institute. For more information, please visit www.alaunos.com.
Investor Relations Contact:
Alex Lobo
Stern Investor Relations
Alex.lobo@sternir.com
May 10, 2022 08:30 ET | Source: Alaunos Therapeutics, Inc.
...
HOUSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced that Kevin S. Boyle Sr., Chief Executive Officer and Drew Deniger, Ph.D., Vice President, Research & Development at Alaunos Therapeutics will present at the upcoming H.C. Wainwright Global Investment Conference being held on May 23-26, 2022 in Miami Beach, FL.
Details for the presentations are below:
Event: H.C. Wainwright Global Investment Conference
Date: Tuesday, May 24, 2022
Time: 5:00-5:30 pm ET
Location: Fontainebleau Miami Beach Hotel
Room: Splash 10
A live webcast of the presentation will be accessible on the Company’s website in the Investors section under Events & Presentations at www.alaunos.com or by using the link here. A replay of the webcast will be available on the Alaunos website for approximately 90 days following the presentation.
About Alaunos Therapeutics
Alaunos is a clinical-stage oncology-focused cell therapy company, focused on developing T-cell receptor (TCR) therapies based on its proprietary, non-viral Sleeping Beauty gene transfer technology and its TCR library targeting shared tumor-specific hotspot mutations in key oncogenic genes including KRAS, TP53 and EGFR. The Company has clinical and strategic collaborations with The University of Texas MD Anderson Cancer Center and the National Cancer Institute. For more information, please visit www.alaunos.com.
Investor Relations Contact:
Alex Lobo
Stern Investor Relations
Alex.lobo@sternir.com